Actualités et vidéos - HOLOGIC INC.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET). The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following each event. About Hologic Hologic, Inc. is an innovative medical technology company...

Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm ® Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures, 1-2 is now CE-marked. The technology received clearance from the U.S. Food and Drug Administration in October 2020. Designed from the ground up to integrate with the Selenia ® Dimensions ® and 3Dimensions™ systems,...

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020. “Our COVID test was instrumental in addressing critical testing needs during the pandemic and offered healthcare providers and laboratories a solution that was highly sensitive and able to help mitigate outbreaks. Nearly five years after the...

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024 . “Our financial results for the first quarter of 2025 were consistent with our guidance overall,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Total revenue finished in line with our guidance on a constant currency basis, and improved profitability helped us post non-GAAP earnings per share at the high end of...

Minicarm.com: Your Go-To Source for Hologic Fluoroscan Mini C-Arm Sales, Parts & Service HAUPPAUGE, NEW YORK / ACCESS Newswire / February 4, 2025 / Hologic has officially announced the End-of-Sale and End-of-Life for the Hologic Fluoroscan InSight FD Mini C-Arm , with sales discontinuing on September 30, 2025. While Hologic has stated they will provide limited service and parts support for up to seven years after installation, units installed in 2018 or earlier will no longer be guaranteed...

Selon le tout dernier rapport Hologic Global Women’s Health Index , l'un des plus grands recueils de données sur la santé et le bien-être des femmes, les examens de dépistage du cancer chez les femmes ont diminué partout dans le monde. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20250121710202/fr/ L'un des principaux acteurs de l'innovation en matière de santé des femmes, s'est associé à Gallup...

Het aantal kankeronderzoeken bij vrouwen is wereldwijd afgenomen, volgens de meest recente Hologic Global Women's Health Index , een van de grootste gegevensverzamelingen op het gebied van de gezondheid en het welzijn van vrouwen. Dit persbericht bevat multimedia. Bekijk hier het volledige persbericht: https://www.businesswire.com/news/home/20250121608260/nl/ Hologic, Inc. (Nasdaq: HOLX), een toonaangevende innovator op het gebied van de gezondheid van de vrouw, werkt samen met Gallup aan de...

Según el último Índice de Salud Global de la Mujer de Hologic , que conforma una de las mayores recopilaciones de datos sobre la salud y el bienestar de la mujer, el número de pruebas de detección del cáncer en las mujeres ha disminuido en todo el mundo. Este comunicado de prensa trata sobre multimedia. Ver la noticia completa aquí: https://www.businesswire.com/news/home/20250121248808/es/ Hologic, Inc. (Nasdaq: HOLX), una empresa innovadora que lidera el sector de la salud femenina,...

Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index , one of the largest collections of data on women’s health and well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/ Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends...

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approximately $1,021.8 million, an increase of 0.9% compared to the prior year period, or 1.0% in constant currency. “Our fiscal Q1 revenue finished in line with our guidance on a constant currency basis, as the strengthening of the U.S. dollar reduced revenue by approximately $9 million compared to when we provided...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following the event. About Hologic, Inc. Hologic, Inc. is an innovative medical technology company...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4103504....

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million. “We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata® System, which complements and expands our range of minimally invasive solutions for heavy...

Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218942183/en/ Panther Fusion® system...

Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening: “Today’s recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective...

Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209400549/en/ Dr. Martin Madaus (Photo: Business Wire) Dr. Madaus, who has more than 30 years of...

Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify postmenopausal women with hormone-receptor positive (HR+), early-stage, node-negative disease who are at minimal risk of experiencing a distant recurrence. Full results will be shared during Poster Session 1 on December 11, 2024, at 12:30 p.m. CT...

Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI ® Detection 2.0 software across diverse patient populations at the 110 th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241202326112/en/ GAI 2.0 (Graphic: Business Wire) Artificial intelligence (AI) is increasingly used to aid in the...

Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110 th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago on December 1-5. On the show floor and during multiple workshops, Hologic will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection. This press release features multimedia. View the full release here:...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21 st , at 10 a.m. Central Time (CT). 7 th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on Tuesday, December 3 rd , at 2:10 p.m. Eastern Time (ET). Citi’s 2024 Global Healthcare Conference in Miami, FL on Wednesday, December 4 th , at 8:45 a.m. ET. Each presentation will be...